📰 Active Controlled Study News
Active Controlled Study News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Active Controlled Study. Real-time updates on events, politics, business and more.
June 10, 2022
NICE Recommends Astellas’ EVRENZO▼™ (roxadustat) For Adults With Symptomatic Anaemia Associated With Chronic Kidney Disease EVRENZOTM (roxadustat) is the first hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor to be recommended by NICE1Over 75,000 adults in England and Wales living with...
December 24, 2020
Posted on 16366 Urovant Sciences (Nasdaq: UROV) announced today that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for once-daily 75 mg GEMTESA® (vibegron), a beta-3 adrenergic receptor (β3) agonist, for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence (UUI), urgency, and urinary frequency in adults. This approval marks the first new oral branded OAB medi...
December 23, 2020
Dec 23, 2020 21:05 UTC Urovant Sciences Announces U.S. FDA Approval of GEMTESA® (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB) IRVINE, Calif. & BASEL, Switzerland--(Business Wire)--Urovant Sciences (Nasdaq: UROV) announced today that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for once-daily 75 mg GEMTESA® (vibegron), a beta-3 adrenergic receptor (β3) agonist, for the treatment of overactive bladder (OAB) wit...